China
Africa
Explore chapters and articles related to this topic
Anion Exchanger in Hypertension
Published in Antonio Coca, Ricardo P. Garay, Ionic Transport in Hypertension: New Perspectives, 2019
On the other hand, the presence of such an abnormality may permit the specific treatment of these patients. In fact, it has been reported that xipamide, a diuretic drug with well-known antihypertensive properties, inhibits in vitro the Na+-dependent Cl−/ AE in human RBC.74 Moreover, it has been suggested that the inhibition of the AE could be involved in the diuretic and/or antihypertensive action of the drug.133 We can therefore hypothesize that xipamide represents the drug of choice for the treatment of hypertensives with increased activity of the Na+-dependent Cl-/ AE.
Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPiRED pilot study
Published in Blood Pressure, 2019
Cora Wunder, Alexandre Persu, Jean-Philippe Lengelé, Coralie MG Georges, Jean Renkin, Agnès Pasquet, Marc Carlier, Zhen-Yu Zhang, Jan A. Staessen
The urine samples were analyzed as described previously [9] using ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS consisting of 1290 LC and 6460 Triple Quadrupole MS from Agilent, Waldbronn, Germany) in the selective and highly sensitive multiple reaction monitoring mode (MRM) for the following 54 antihypertensive drugs and metabolites: aliskiren, altizide, amiloride, amlodipine, atenolol, azilsartan, barnidipine, benazepril/benazeprilat, bendroflumethiazide, bisoprolol, bumetanide, candesartan, carvedilol, chlortalidone, clonidine, diltiazem, doxazosin, enalapril/enalaprilat, eprosartan, felodipine, furosemide, hydrochlorothiazide (HCT), irbesartan, lercarnidipine, lisinopril, losartan, metoprolol, minoxidil, molsidomine, moxonidine, nebivolol, nifedipine, nitrendipine, olmesartan, perindopril/perindoprilat, piretanide, prazosin, quinapril/quinaprilat, ramipril/ramiprilat, spironolactone/canrenone, telmisartan, terazosin, torasemide, triamterene, urapidil, valsartan, verapamil and xipamide.
Preventable ADRs leading to hospitalization — results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients
Published in Expert Opinion on Drug Safety, 2018
S Schmiedl, M Rottenkolber, J Szymanski, B Drewelow, W Siegmund, M Hippius, K Farker, I R Guenther, J Hasford, P A Thuermann
For seven compounds associated with an increased risk of developing a preventable ADR (digitoxin, diclofenac, glyburide, spironolactone, torasemide, xipamide, and intermediate-acting insulin), an estimation of ADR incidence rates was calculated for patients aged <70 years and ≥70 years. Irrespective of age groups, incidence rates for non-preventable ADRs were higher compared with preventable ADRs for all drugs. Highest incidence rates for preventable ADRs were estimated for patients aged ≥70 years receiving xipamide (2.5 per 1,000 exposed persons (95% CI: 1.0–5.2)), intermediate-acting insulin (3.3 per 1,000 exposed persons (95% CI: 1.6–6.1)), and spironolactone (3.3 per 1,000 exposed persons (95% CI: 1.4–6.6), Figure 3).